Search
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
Anagliptin
go.drugbank.com/drugs/DB12417InvestigationalAnagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.
Categories: DPP-IV InhibitorsNTx-265
go.drugbank.com/drugs/DB05649InvestigationalIn May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Toloxatone
go.drugbank.com/drugs/DB09245ExperimentalToloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].
Alethine
go.drugbank.com/drugs/DB05800InvestigationalIt is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models. … Alethine is studied in the treatment of cancer. It belongs to a family of chemicals called disulfides.
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting, combination with Ruxolitinib in myelofibrosis), NCT04655118 (recruiting, myelofibrosis), NCT04669067 (active, not recruiting
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalIt was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
Afelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.